What usually causes posttransplant lymphoproliferative disease?
Select Your Answer:
The single most important risk factor for posttransplant lymphoproliferative disease (PTLD) is Epstein-Barr virus (EBV) exposure.
The greatest risk is with EBV-positive donor organs being transplanted to EBV-negative recipients.
When B-cell lymphocytes are infected with EBV, B-cell transformation can occur. In immunocompetent patients, transformed B-cell proliferation usually is mediated by cytotoxic T cells.
However, the immunosuppression required after transplantation impairs T-cell immunity, which can lead to uncontrolled proliferation of transformed B-cells. This ultimately can lead to lymphoma.
Adult Lab Normals
Pediatric Lab Normals
Cancer risk following organ transplantation: a nationwide cohort study in Sweden., Adami J,Gäbel H,Lindelöf B,Ekström K,Rydh B,Glimelius B,Ekbom A,Adami HO,Granath F,, British journal of cancer, 2003 Oct 6 [PubMed PMID: 14520450]
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study., Curtis RE,Travis LB,Rowlings PA,Socié G,Kingma DW,Banks PM,Jaffe ES,Sale GE,Horowitz MM,Witherspoon RP,Shriner DA,Weisdorf DJ,Kolb HJ,Sullivan KM,Sobocinski KA,Gale RP,Hoover RN,Fraumeni JF Jr,Deeg HJ,, Blood, 1999 Oct 1 [PubMed PMID: 10498590]
Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?, Nelson BP,Nalesnik MA,Bahler DW,Locker J,Fung JJ,Swerdlow SH,, The American journal of surgical pathology, 2000 Mar [PubMed PMID: 10716151]
Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience., Allen U,Hébert D,Moore D,Dror Y,Wasfy S,, Pediatric transplantation, 2001 Jun [PubMed PMID: 11422823]
Post-transplant lymphoproliferative disorders., Singavi AK,Harrington AM,Fenske TS,, Cancer treatment and research, 2015 [PubMed PMID: 25655616]
Infection in organ transplantation: risk factors and evolving patterns of infection., Fishman JA,Issa NC,, Infectious disease clinics of North America, 2010 Jun [PubMed PMID: 20466270]
Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?, Bakker NA,van Imhoff GW,, Haematologica, 2007 Nov [PubMed PMID: 18024391]
Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders., Cen H,Williams PA,McWilliams HP,Breinig MC,Ho M,McKnight JL,, Blood, 1993 Mar 1 [PubMed PMID: 8382973]
Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States., Dharnidharka VR,Lamb KE,Gregg JA,Meier-Kriesche HU,, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012 Apr [PubMed PMID: 22226225]
Post-Transplantation Lymphoproliferative Disorders in Adults., Dierickx D,Habermann TM,, The New England journal of medicine, 2018 Feb 8 [PubMed PMID: 29414277]
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial., Trappe R,Oertel S,Leblond V,Mollee P,Sender M,Reinke P,Neuhaus R,Lehmkuhl H,Horst HA,Salles G,Morschhauser F,Jaccard A,Lamy T,Leithäuser M,Zimmermann H,Anagnostopoulos I,Raphael M,Riess H,Choquet S,, The Lancet. Oncology, 2012 Feb [PubMed PMID: 22173060]